Suppr超能文献

激素替代疗法与肺动脉高压:文献综述

Hormone Replacement Therapy and Pulmonary Hypertension: A Review of the Literature.

作者信息

Gill Natasha K, Sohi Supreet K, Joseph Girish, Bhatti Neena

机构信息

Internal Medicine, University Hospitals Parma Medical Center, Parma, USA.

Medicine, Rajendra Institute of Medical Sciences, Patiala, IND.

出版信息

Cureus. 2024 Oct 20;16(10):e71908. doi: 10.7759/cureus.71908. eCollection 2024 Oct.

Abstract

Pulmonary hypertension (PH) is a multifactorial condition that encompasses a group of diseases characterized by a progressive increase in pulmonary vascular resistance and pulmonary arterial pressure, ultimately leading to right heart failure and death. The primary goals of PH treatment are to lower pulmonary arterial pressure, alleviate symptoms such as shortness of breath and chest pain, address modifiable risk factors, and manage the underlying cause, often a common advanced disease like chronic obstructive lung disease or left heart disease. While sex is an unchangeable risk factor for PH development, the presence or absence of estrogens has a significant influence on its progression. Hormone replacement therapy (HRT) is the recommended form of estrogen therapy for postmenopausal women, but only in carefully selected cases. However, a paradox arises, as some research suggests HRT benefits women, while other studies highlight its risks. This review provides a comprehensive analysis of the literature on the role of HRT in PH.

摘要

肺动脉高压(PH)是一种多因素疾病,涵盖一组以肺血管阻力和肺动脉压力逐渐升高为特征的疾病,最终导致右心衰竭和死亡。PH治疗的主要目标是降低肺动脉压力,缓解诸如呼吸急促和胸痛等症状,处理可改变的风险因素,并治疗潜在病因,潜在病因通常是诸如慢性阻塞性肺疾病或左心疾病等常见的晚期疾病。虽然性别是PH发生的不可改变的风险因素,但雌激素的存在与否对其进展有重大影响。激素替代疗法(HRT)是绝经后女性推荐的雌激素治疗形式,但仅适用于经过精心挑选的病例。然而,出现了一个悖论,因为一些研究表明HRT对女性有益,而其他研究则强调其风险。本综述对关于HRT在PH中的作用的文献进行了全面分析。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/6f82/11576071/4f290ec36d72/cureus-0016-00000071908-i01.jpg

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验